Immune-mediated necrotizing myopathy
MONDO:0016098Necrotizing autoimmune myopathy (NAM) is a rare form of idiopathic inflammatory myopathy characterized clinically by acute or subacute proximal muscle weakness, and histopathologically by myocyte necrosis and regeneration without significant inflammation.
Also known as: IMNM, NAM, anti-HMG-CoA myopathy, anti-SRP myopathy, autoimmune necrotizing myositis, immune myopathy with myocyte necrosis, necrotizing autoimmune myopathy
25 clinical trials for this condition and its sub-types, 17 tagged with Immune-mediated necrotizing myopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can engineered immune cells stop a rare muscle disease?
Cure Not yet recruitingThis early-stage trial is testing whether a personalized cell therapy called Eque-cel can safely and effectively treat people with refractory immune-mediated necrotizing myopathy (IMNM), a severe autoimmune condition that causes muscle weakness and damage. The therapy involves re…
Phase 1/2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…
Phase 1 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC